SCHEMBL19667418

SCHEMBL19667418

Cc1ncnc2c1ccn2[C@H]1C=C[C@@H](OC(=O)O[C@@H]2C=C[C@H](n3ccc4c(C)ncnc43)C2)C1

nearest known ligand 0.39

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ ADCY5 O95622 6/20 0.39
▸ PRMT5 O14744 12/20 0.38
▸ ACACB O00763 2/20 0.37
▸ WDR77 Q9BQA1 6/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19667419 0.92 ADCY5 (0.40) ADCY5PRMT5WDR77
SCHEMBL19667277 0.91 PRMT5 (0.37) ADCY5PRMT5ACACBWDR77
SCHEMBL19684699 0.86 PRMT5 (0.39) PRMT5WDR77
SCHEMBL19667421 0.80 PRMT5 (0.42) PRMT5WDR77
SCHEMBL23535896 0.79 NNMT (0.38) ADCY5
SCHEMBL30207974 0.79 PRMT5 (0.39) PRMT5WDR77
SCHEMBL19667368 0.79 PRMT5 (0.39) PRMT5WDR77
SCHEMBL19679203 0.78 PRMT5 (0.38) PRMT5WDR77
SCHEMBL19667639 0.78 PRMT5 (0.41) PRMT5WDR77
SCHEMBL30207833 0.78 PRMT5 (0.41) PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3464249-B1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER (US) 2021-08-11 — — EP disclosed
US-10709709-B2 Substituted carbonucleoside derivatives useful as anticancer agents PFIZER INC. (US) 2020-07-14 — — US disclosed
US-20190111060-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2019-04-18 — — US disclosed
US-10220037-B2 Substituted carbonucleoside derivatives useful as anticancer agents PFIZER INC. (US) 2019-03-05 — — US disclosed
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2017-12-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10709709-B2 Substituted carbonucleoside derivatives useful as anticancer agents DUT, NCL, TYMP ADCY5 3640/4885PRMT5 1945/4885ACACB 2353/4885
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS DUT, NCL, TYMP ADCY5 3640/4885PRMT5 1945/4885ACACB 2353/4885
US-20190111060-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS DUT, NCL, TYMP ADCY5 3640/4885PRMT5 1945/4885ACACB 2353/4885
US-10220037-B2 Substituted carbonucleoside derivatives useful as anticancer agents DUT, NCL, TYMP ADCY5 3640/4885PRMT5 1945/4885ACACB 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback